Can a Psychedelic From Toad Venom Help When Antidepressants Fail?
Summary
A Phase 2b trial found that an investigational nasal spray containing 5-MeO-DMT, a short-acting psychedelic derived from Colorado River toad venom, reduced symptoms in people with treatment-resistant depression. The study reported higher remission rates among participants who received the active dose than among those who received an inactive dose, with benefits observed about a month after treatment.Key Facts
- The study included 193 people with treatment-resistant depression, defined as an inadequate response to at least two antidepressants.
- Participants received an active or inactive dose of the drug through a nasal spray.
- The eight-week trial took place at 38 sites in Australia, Germany, Poland, Spain, the U.K. and the U.S.
- About a month after treatment, remission rates were 18 to 26 percent among participants who received the active dose, compared with 8 percent in the inactive-dose group.
- Researchers said most participants could leave the treatment site within two hours of taking the drug.
- The study was published in JAMA on October 26 and funded by Eli Lilly.
- Eli Lilly said it plans to evaluate the investigational treatment in a Phase 3 program.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
